Leading infectious disease experts in Russia recognized the efficacy of Avifavir®

The high efficacy of Avifavir®, the first registered drug for the treatment of COVID-19, in clinical practice was recognized at the All-Russian Congress on Infectious Diseases.

Last week saw the closing of the 13th All-Russian Congress on Infectious Diseases named after academician V.I. Pokrovsky “Infectious Diseases in the Modern World: Current and Future Threats”, which was attended by many medical leaders, infectious disease scientists, epidemiologists, practitioners, and other researchers from all over the world.

And certainly, the main topic of the Congress was the fight against COVID-19, national biosafety, and fast response to biological threats. At one of the scientific sessions, Doctor of Medicine Andrey Devyatkin, who is a professor of infectious diseases at the Department of Family Medicine of the Federal State Budgetary Institution DPO “TsGMA” UD of the President of the Russian Federation and the Head of the course of infectious diseases at the Faculty of Fundamental Medicine of Moscow State University named after M.V. Lomonosov, spoke about the pathophysiological features and treatment tactics for COVID-19, as well as shared the results of a clinical trial and his personal experience of using Avifavir® against COVID-19.

Professor A.V. Devyatkin noted the efficacy of Avifavir® in the combined treatment of patients with COVID-19. Clinical improvement and discharge from the hospital were observed significantly earlier in patients taking Avifavir® in combination with pathogenetic and symptomatic therapy. Thanks to such treatment, elimination of the virus and prevention of its further spread were achieved faster. It should be noted that rapid recovery of patients also helped reduce the period of their disability and isolation.

Photo: Professor A.V. Devyatkin, Doctor of Medicine, giving his speech at the Congress

During the scientific discussion, the specialists analyzed contraindications and warnings for the appointment of favipiravir. Professor Devyatkin emphasized that Avifavir® has shown favorable safety features in real clinical practice, both in inpatient and outpatient environments, thereby proving the data obtained during the clinical trial. He also recommended prescribing Avifavir® to patients from the very first days of the disease.

Avifavir® is a Russian drug with proven clinical efficacy against COVID-19.

Avifavir® is the world’s first approved favipiravir-based drug against COVID-19 and the first drug against COVID-19 registered in Russia.

Chromis, a joint venture of the Russian Direct Investment Fund (RDIF) and ChemRar Group, was established in 2020 to develop and market Avifavir, a favipiravir-based drug against COVID-19. The trials carried out by a number of leading medical and scientific centers proved that the drug is highly effective and safe so that it was registered in Russia for the treatment of COVID-19. The Ministry of Health of the Russian Federation approved the permanent registration of Avifavir® on November 6, 2020.

The All-Russian Congress on Infectious Diseases named after academician V.I. Pokrovsky is held annually by the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing and scientific institutions of Rospotrebnadzor. In total, 13,000+ people took part in the Congress online and in person.